Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Xu Zhang,Guozhen Yang,Xiaodong Su,Guangyu Luo,Peiqiang Cai,Yating Zheng,Ting Bei,Chan Gao,Mengli Huang

CANCER RESEARCH（2021）

引用 37|浏览19

暂无评分

摘要

Neoadjuvant camrelizumab plus nab-paclitaxel and S1 is safe, feasible and effective in locally advanced ESCC and is worth further investigation.

查看译文

关键词

Anti-programmed death-1 (PD-1),esophageal squamous cell carcinoma (ESCC),neoadjuvant therapy,tumor immune microenvironment (TIME),tumor mutational burden (TMB)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要